Navigation Links
Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics
Date:7/7/2009

SOUTH SAN FRANCISCO, Calif., July 7 /PRNewswire/ -- Catalyst Biosciences, Inc. today announced the signing of an exclusive worldwide research and license agreement with MedImmune, the global biologics unit of AstraZeneca plc, to develop novel engineered proteases that specifically degrade or modulate two targets, one of which will address inflammatory and autoimmune diseases.

Catalyst will receive undisclosed upfront licensing fees, full-time employee (FTE) support and milestone payments totaling up to $195 million, exclusive of royalty payments, for the development of drug candidates against two distinct targets.

Through the collaboration, MedImmune will support the discovery research and preclinical development by Catalyst of Alterase(TM) therapeutics against an undisclosed target, with an option to expand the agreement to include a second target. Alterase therapeutics are next-generation, protease biologics engineered with the ability to catalytically cleave and inactivate disease-causing proteins. MedImmune will be responsible for all development, manufacturing, and commercialization efforts associated with the products discovered through the collaboration in exchange for future milestones and royalties.

"We are very pleased to add MedImmune, a leading developer of biologic therapies, as a partner," said Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences. "Our Alterase drug discovery engine is creating novel next-generation protein therapeutics against a broad variety of important disease targets. Collaborations such as this demonstrate the high value of our discovery and protein engineering capabilities."

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide a
'/>"/>

SOURCE Catalyst Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results
4. Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction
5. CATalyst Summit Declared a Success: Its All About the Cat!
6. Cardiva Medical, Inc. to Present Highlights of the Boomerang Catalyst(TM) II System at the Investment in Innovation (In3) West Conference on February 29, 2008 in Las Vegas, NV
7. Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
8. Case in Point: Patient Control of Data Critical Catalyst for Online Health Care Revolution
9. Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap(R) Index
10. Congress Approves ePrescribing Initiative in Medicare Reform Bill: Critical Catalyst in Driving a New Generation of Prescribing
11. CATalyst Council Forms to Address Feline Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... A group of 127 scientists sent an “open ... to a recent statement by the center that was highly ... the efficacy of all brain exercises. , Signatories to the ... the center’s statement critical of brain exercise companies that overstate ... its case, in a document it had entitled “A Consensus ...
(Date:12/17/2014)... No matter how far modern medicine advances, it ... louse parasite—a common childhood malady and a source of ... and twelve million individuals will suffer an infestation. ... comes to the rescue, providing an all-natural treatment that ... record of customer service, and effectiveness in getting rid ...
(Date:12/17/2014)... Project Veritas is releasing a video interview ... economist and Obamacare architect Jonathan Gruber to public attention. ... interview, which is being distributed on YouTube. , During ... in the Affordable Care Act in order to hide ... dollar per year tax grab. , “President Obama promised ...
(Date:12/17/2014)... Alan Mozes HealthDay Reporter ... world of infectious diseases, one worrisome phenomenon is when an ... The process -- known as zoonosis -- is not uncommon ... signs that an animal-borne disease might make inroads into the ... a development -- and the culprits in this case were ...
(Date:12/17/2014)... students get more fruits and vegetables at school than they ... opposite is true for students from wealthier families. These ... give a healthy boost to poor students, diets, according to ... level, students all ate a similar amount of fruits and ... published recently in the journal Preventive Medicine . ...
Breaking Medicine News(10 mins):Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Poor Students Eat Healthier Foods at School, Study Finds 2
... of Meijer ... customers, ... Legacy of Leadership award in recognition of its free,antibiotic and free ... Service Awards luncheon of Michigan,Primary Care Association (MPCA), the nonprofit membership ...
... CHAPEL HILL A new study seeking to improve scientists, ... is higher in African-American women, is getting underway in 44 ... late Jeanne Hopkins Lucas, a North Carolina state senator who ... the Lineberger Comprehensive Cancer Center at the University of North ...
... time, increase physician productivity,and safety, WASHINGTON, ... wait time, and improve quality of care, ... voluntary consensus standards for,hospital-based emergency department care. ... coordination in emergency departments where high demand,and ...
... Corporation Award Based on Consistent, Long-term Revenue Growth, ... HSKA ) ("Heska") today announced it has ... by Deloitte LLP. The Technology Fast,50 lists the ... companies in Colorado based on percentage revenue growth ...
... type 1 a rare disease in which tumors grow ... by crosstalk between cells in the nerves and cells in ... National Institutes of Health (NIH) and the Department of Defense ... treating certain kinds of blood cancer curbs tumor growth in ...
... - Response Biomedical,Corporation (TSX: RBM, OTCBB: RPBIF) announces ... Rapid Detection Flu A+B Test at the 48th ... launching,the RAMP(R) Influenza A/B Assay in the United ... 3M(TM) Rapid Detection Flu A+B Test. This rapid ...
Cached Medicine News:Health News:Meijer Honored by Michigan Primary Care Association for Leadership in Promoting Health of Michigan Residents 2Health News:Meijer Honored by Michigan Primary Care Association for Leadership in Promoting Health of Michigan Residents 3Health News:UNC Lineberger launches 44-county study of breast cancer in black women 2Health News:UNC Lineberger launches 44-county study of breast cancer in black women 3Health News:NQF Endorses Measures to Address Care Coordination and Efficiency in Hospital Emergency Departments 2Health News:NQF Endorses Measures to Address Care Coordination and Efficiency in Hospital Emergency Departments 3Health News:Deloitte Names Heska Corporation to Colorado Technology Fast 50 2Health News:Deloitte Names Heska Corporation to Colorado Technology Fast 50 3Health News:Researchers identify mechanism, possible drug treatment for tumors in neurofibromatosis 2Health News:Researchers identify mechanism, possible drug treatment for tumors in neurofibromatosis 3Health News:Response Biomedical Announces Launch of RAMP(R) Technology in 3M(TM) Rapid Detection Flu A+B Test at ICAAC/IDSA Conference 2Health News:Response Biomedical Announces Launch of RAMP(R) Technology in 3M(TM) Rapid Detection Flu A+B Test at ICAAC/IDSA Conference 3Health News:Response Biomedical Announces Launch of RAMP(R) Technology in 3M(TM) Rapid Detection Flu A+B Test at ICAAC/IDSA Conference 4
(Date:12/15/2014)... and BRIDGEWATER, N.J. , ... REGN) and Sanofi US (EURONEXT: SAN and NYSE: SNY) ... organizations to launch Cholesterol Counts , an awareness ... cholesterol, their numbers, and the risks associated with high ... www. CholesterolCounts .com to take a brief ...
(Date:12/15/2014)... , Dec. 15, 2014   DaVita ... one of the nation,s largest and most innovative ... its business units, DaVita Clinical Research  (DCR) and  ... to further expand its extensive clinical research and ... kidney disease (CKD) and end-stage renal disease (ESRD), ...
(Date:12/13/2014)... , December 12, 2014 ... announced the addition of the  "Global Catheters ... Share, Global Trends, Company Profiles, Analysis, Segmentation ... to their offering.       (Logo: ... made up of medical grade material such ...
Breaking Medicine Technology:Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4Global Catheters Market (Product Types and Geography) - Forecast to 2020 2Global Catheters Market (Product Types and Geography) - Forecast to 2020 3
... 2, 2011 Aoxing Pharmaceutical (NYSE Amex: ... company focusing on research, development, manufacturing and distribution ... operating subsidiary in China, Hebei Aoxing Pharmaceutical Group ... State Intellectual Property Office of The People,s Republic ...
... TARRYTOWN, N.Y., May 2, 2011 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... of America Merrill Lynch 2011 Health Care Conference on Tuesday, ... Eastern Time).  The session may be accessed through the Company,s ...  An archived version of the presentation will be available after ...
Cached Medicine Technology:Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film 2Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film 3
... of a heartbeat. The bodys warmth beneath ... These vital signs are yours to guard, ... of Temperature Monitoring products helps you do ... to provide the most comfortable and precise ...
... The bodys warmth beneath drapes. The life-giving ... are yours to guard, measure, stabilize and ... products helps you do your job, giving ... most comfortable and precise management of your ...
... stabilization of the capsular bag in complicated ... Tension Ring has application in several different ... available for patients with pseudoexfoliation syndrome. Many ... tension ring, especially those in whom you ...
... The Smartlipo laser provokes the breaking ... adipose cells, transforming them into an ... eliminated in a natural manner. ... harmonious body shape in a short ...
Medicine Products: